Ocrevus Safety Profile & Adverse Events

Safety Profile Overview

Anti-CD20 antibody for relapsing and primary progressive MS. First therapy approved for PPMS. Monitored for infusion reactions and infections.

Generic Name

ocrelizumab

Brand Names

Ocrevus

Therapeutic Class

Anti-CD20 Monoclonal Antibody

Manufacturer

Roche/Genentech

What Pharma Signal Tracks for Ocrevus

Adverse Events (FAERS) — All FDA Adverse Event Reporting System reports mentioning Ocrevus, including serious outcomes, hospitalizations, and deaths.
FDA Recalls — Class I, II, and III recalls, market withdrawals, and safety alerts related to Ocrevus products.
Label Changes — Boxed warning additions, new contraindications, dosing modifications, and safety-related labeling supplements.
Risk Score — Composite risk score (0–100) combining adverse event rates, recall history, and label severity with explainable breakdown.
Pharmacovigilance Signals — Proportional Reporting Ratio (PRR) and Reporting Odds Ratio (ROR) analysis detecting disproportionate adverse reactions.
Trend Analysis — Monthly time series with anomaly detection for emerging safety signals.

Data Disclaimer: Pharma Signal aggregates data from the FDA Adverse Event Reporting System (FAERS) and other public regulatory sources. FAERS reports do not establish causation. Report counts may reflect prescription volume rather than relative safety. Always consult healthcare professionals for medical decisions.

Get Ocrevus Safety Data via API

One API call returns adverse events, risk scores, recalls, and pharmacovigilance signals for Ocrevus.

curl "https://api.pharma-signal.com/drug/safety/ocrevus" \
  -H "X-API-Key: your_key"

# Returns risk score, adverse event counts,
# serious/death rates, recalls, and signals

Try the API API Reference

Related Safety Intelligence

Pharma Signal provides comparative analysis across therapeutic classes. Compare Ocrevus against other Anti-CD20 Monoclonal Antibody drugs, or explore the full manufacturer portfolio for Roche/Genentech.

Head-to-head comparison — Compare up to 5 drugs side by side on all safety metrics.
Therapeutic class benchmarking — See how Ocrevus ranks within Anti-CD20 Monoclonal Antibody on serious event rates.
Company portfolio risk — View all drugs from Roche/Genentech with aggregate risk exposure.
AI analyst briefs — Get a natural-language safety assessment combining all data sources.